Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients (MSC11FCD-GBM)

Investigator-initiated and Open-labeled Clinical Trial for Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients

This is a phase I trial evaluating the maximum tolerated dose, safety and efficiency of Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD), injected into the resection cavity of patients with recurrent glioblastoma.

Study Overview

• Status: Completed
• Conditions: Neoplasms, Germ Cell and Embryonal; Glioblastoma; Recurrent Glioblastoma; Adult Gliosarcoma; Neoplasms, Brain
• Intervention / Treatment: Drug: MSC11FCD

Detailed Description

Not Provided

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• Korea, Republic of
  • Kyunggido
    • Seongnam, Kyunggido, Korea, Republic of, 13496
      • Bundang Cha Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 19 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Patients aged 19 to 70
2. Patients diagnosed with recurrent glioblastoma based on medical imaging after receiving standard therapy for glioblastoma
3. Patients scheduled to undergo surgical treatment for recurrent glioblastoma
4. Patients diagnosed with recurrent glioblastoma based on medical imaging (MRI: conventional, diffusion, perfusion, spectroscopy) and confirmed to have tumor cells during surgery based on frozen biopsy
5. Patients whose expected survival period is at least 3 months
6. Patients who have not received any other types of immunotherapy
7. Patients who have been given a sufficient explanation of the purpose and details of the clinical trial and the characteristics of the investigational drug from an investigator and who signed the consent form or had a legal guardian or representative sign the consent form prior to the beginning of this clinical trial
8. Patients who have waited for at least four weeks after treatment using cytotoxic drugs in order to eliminate the possibility of impact and effects from other therapeutic agents (23 days after the last administration in case of undergoing standard therapy using temozolomide)

Exclusion Criteria:

1. Patients who have primary glioblastoma
2. Patients with dihydropyrimidine dehydrogenase (DPD) deficiency
3. Patients who cannot undergo a contrast (gadolinium) enhanced MRI scan due to a certain condition (pacemaker, etc.) or cannot undergo an MRI scan according to the clinical trial schedule due to any other reasons
4. Patients to whom Gliadel water was applied during surgery
5. Patients who are deemed to have a serious dysfunction in any of the major organs (liver, kidneys, bone marrow, lungs, heart) by the investigator
6. Patents who have other types of malignant tumor aside from glioblastoma or who have had malignant tumor in the past 5 years
7. Patients who uncontrolled hypotension or hypertension
8. Diabetic patients who are currently receiving insulin therapy or who need insulin therapy
9. Patients who are deemed to have a serious infectious disease by the investigator: sepsis, hepatitis A, hepatitis B or hepatitis C (in the case of hepatitis B and C viruses, however, carriers may be enrolled at the investigator's discretion) or tested positive in a serological test for the human immunodeficiency virus (HIV)
10. Karnofsky Performance Scale < 60
11. Patients with an autoimmune disease affecting the central nervous system (multiple sclerosis, myasthenia gravis, acute disseminated encephalomyelitis, etc.)
12. Patients with a history of allergic reactions to flucytosine (5-FC) and/or its excipients or 5-fluorouracil (5-FU)
13. Pregnant or lactating women or patients who plan on getting pregnant during the clinical trial or refuses to choose an appropriate method of contraception
14. Patients who have participated in a different clinical trial no more than 30 days prior to registering for this clinical trial
15. Patients who are deemed to be unfit for this clinical trial by the investigator

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: The investigational drug into the Intratumoral administration; The investigational drug in the amount of 1x10^7, 3x10^7cells per dose into the tumor or the tumor removal site using a syringe during surgery

Drug: MSC11FCD; Administration period: Single dose Route of administration: Intratumoral administration Dose: 1x10^7, 3x10^7cells/dose Summary: Administer the investigational drug in the amount of 1x107, 3x107cells per dose into the tumor or the tumor removal site using a syringe during surgery. Concomitant drug: 5-Flucytosine (prodrug) Dose: 150mg/kg/day Directions: Administration period and directions: Administer 150m of 5-Flucytosine per kilogram of body weight every 6 hours for a total of 4 times a day (QID) for a duration of 7 days after surgery. Route of administration: Oral administration; Other Names: Mesenchymal stem cells into which the suicide gene, cytosine deaminase (CD)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximum tolerated dose (MTD)	Assessment of the maximum tolerated dose based on the 3+3 method; Blood concentrations of 5-FC and 5-FU(Day 1, Day 3, Day 7); MSC11FCD concentrations (MSCCD detection) (Day 0, 3months, 6months, 12months)	after treatment discontinuation for approximately 1 years
Number Of Adverse Events related to the treatment	Evaluate the number of adverse event related to the treatment according to CTCAE V4.0 during the trial (including clinically significant changes in physical examination, radiographic images, safety lab tests, vital signs)	Baseline, Day0, 1 month, 3 months, 6 months, 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival improvement (OS)	OS is defined as the time from the date of MSC injection to the date of death due to any cause.	Study entry through the end of the study, up to 12 months
Progression Free Survival (PFS)	The progress-free survival analysis shall be based on the RANO criteria.	Study entry through the end of the study, up to 12 months
Tumor assessment in regard to the investigational drug based on the RANO criteria	Assess the treatment groups participating in this clinical trial based on the RANO criteria. Compare and present the disease control rates by calculating the ratio of the number of subjects responding to treatment (complete response: CR, partial response: PR, stable disease: SD) among the treatment groups and control group assessed based on the RANO criteria.	At Baseline, 1month, 3months, 6months, 12months
Clinical efficacy assessment	Karnofsky performance status (KPS) assessment	At Baseline, 1month, 3months, 6months, 12months

Collaborators and Investigators

• Sponsor: CHA University
• Collaborators: Ajou University School of Medicine
• Investigators: Principal Investigator: Kyunggi Cho, MD,PhD, CHA University

Study record dates

Study Major Dates

• Study Start (Actual): June 24, 2020
• Primary Completion (Actual): December 22, 2022
• Study Completion (Actual): December 22, 2022

Study Registration Dates

• First Submitted: November 1, 2020
• First Submitted That Met QC Criteria: December 5, 2020
• First Posted (Actual): December 8, 2020

Study Record Updates

• Last Update Posted (Actual): January 18, 2023
• Last Update Submitted That Met QC Criteria: January 14, 2023
• Last Verified: January 1, 2023

More Information

Terms related to this study

• Keywords: Brain Tumor; Flucytosine; Central Nervous System Neoplasms; Glioblastoma, Mesenchymal stem cells; Neoplasms, Germ Cell
• Additional Relevant MeSH Terms: Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neoplasms by Histologic Type; Neoplasms by Site; Neoplasms, Glandular and Epithelial; Disease Attributes; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Nerve Tissue; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms; Neoplasms, Germ Cell and Embryonal; Glioblastoma; Recurrence; Brain Neoplasms; Gliosarcoma
• Other Study ID Numbers: CHAMC 2019-08-022

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No